Kaitlyn Bader, Senior Editor

This week’s collection of the latest dermatologic studies covers ligelizumab for the treatment of chronic spontaneous urticaria, AI for the early detection of skin cancer, blood pressure monitoring for minoxidil therapy in alopecia patients, and aminolevulinic acid 20% solution plus blue light PDT for the treatment of AKs.

Systemic corticosteroids are often used as primary therapy for PG, but alternatives should be considered for their favorable safety profile.

ICYMI, this week we had articles about a CME credit opportunity on the pathogenesis of HS, Paul Friedman, MD, reviewing UltraClear Laser-Coring, Journey Medical Corporation submitting its NDA for DFD-29 for the treatment of rosacea, and more.

J3401 went into effect on January 1, 2024.

Paul Friedman, MD, discusses the benefits of UltraClear Laser-Coring, patient downtime, how to decide what devices to have in your clinic, and more.

SKNJCT-003 is expected to enroll up to 60 patients.

As 2023 comes to a close, Dermatology Times is taking a look back at the updates and advances from nurse practitioners and physician assistants this year.

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in skin cancer this year.

Find out what the top 10 most popular articles of 2023 were from Dermatology Times.

Catch up on Dermatology Times conference coverage from January through June of this year.

Catch up on coverage of FDA-approved drugs in 2023.

ICYMI, this week we had articles about vitiligo onset following COVID-19 vaccination, a Revolutionzing Vitiligo interview with Nanette Silverberg, MD, the FDA approval of Filsuvez for the treatment of partial thickness wounds related to dystrophic junctional and epidermolysis bullosa, and more.

Learn more about the in-depth topics covered in the December 2023 print issue of Dermatology Times.

The study findings were presented in a poster at the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

Lisa Swanson, MD, FAAD, and Robert Casquejo, PA-C, discuss their preferred treatment approach for plaque psoriasis, which includes PDE4 inhibitors such as apremilast and roflumilast.

Review a rundown of our top articles and resources for patients inspired by National Eczema Awareness Month.

At 3 years, V940 plus pembrolizumab reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62%.

Here is a recap of the drugs and treatments approved to keep in mind for the new year.

ICYMI, this week we had articles about coverage from the Revolutionizing Atopic Dermatitis and Vitiligo virtual conferences, expert insights on AAD's updated AD management guidelines, positive data of axitinib for basal cell carcinoma, and more.

Roflumilast foam 0.3% is the first FDA-approved drug for seborrheic dermatitis with a new mechanism of action in over 2 decades. Christopher Bunick, MD, PhD; Shawn Kwatra, MD; and Peter Lio, MD, share expert insights.

David Rosmarin, MD, presented new and upcoming pipeline updates for the treatment of vitiligo at the Revolutionizing Vitiligo Virtual Conference.

Biolojic’s BD9 is a dual specific antibody that can block both Thymic stromal lymphopoietin and IL-13.

One of the specific areas of focus will be non-melanoma skin cancer.

Hyaluronic acid fillers and biostimulators were a couple of Prather's recent favorite aesthetic advancements.

This week’s collection of the latest dermatologic studies covers skin cancer risk associated with phototherapy excluding psoralens, the role of the mycobiome in the development of atopic diseases, underrecognized pediatric vulvar diseases, and sunscreen deserts in Northeast, Ohio.

From the December cover feature: Christopher Bunick, MD, PhD; Aaron Drucker, MD, ScM; and Mona Shahriari, MD, share their thoughts on AAD’s updated atopic dermatitis guidelines.

Jennifer Etienne shared her experiences during the shared decision-making patient panel of the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

The promising data on upadacitinib was presented at the 2023 Revolutionizing Vitiligo Virtual Conference.

ICYMI, this week we had articles about upcoming conferences in 2024, the potential causal relationship between pure hypercholesterolemia and psoriasis, the first patient dosed in Kymera's phase 2 AD trial, and more.

This week’s collection of the latest dermatologic studies covers the burden of pediatric AD, skin cancer risk associated with combined methotrexate and NB-UVB therapy in patients with moderate to severe PsO, stigma towards patients with acne, and detection of nonmelanoma skin cancers in Mohs surgical sections using deep learning.